NEOVACS ANNOUNCES THAT ITS PARTNER BIOSENSE GLOBAL HAS EXERCISED ITS OPTION TO ACQUIRE THE EXCLUSIVE LICENCE FOR IFNalpha KINOID TO TREAT LUPUS IN CHINA - Seite 2
About Biosense Global LLC
BioSense is an emerging biotech company established to address the business needs of the global biopharmaceutical market with a focus on China, Europe, and the U.S. The company is based in New
Jersey (US) and Suzhou (China). The organization's mission is to bridge the gap between undercapitalized biopharmaceutical projects, companies, and investors to add value to its stakeholders and
address significant unmet medical needs. BioSense's expert team of international biopharma executives and seasoned investors has extensive experience in developing, registering and commercializing
some of the most successful products in key markets, including, US, Europe and China, plus the business management and cross-cultural knowledge while navigating entry into new markets and access to
additional resources and funds.
http://www.biosensegloballlc.com/about/
About Neovacs
Listed on Euronext Growth since 2010, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or
inflammatory diseases. On the basis of the company's proprietary technology for inducing a polyclonal immune response (covered by four patent families that potentially run until 2032) Neovacs is
focusing its clinical development efforts on IFNalpha Kinoid, an immunotherapy being developed for the indication of lupus, dermatomyositis and also in preclinical trial for Type 1 diabetes.
Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology and allergies. The goal of the Kinoid approach is to enable
patients to have access to safe treatments with efficacy that is sustained in these life-long diseases. www.neovacs.fr
Contact
Lesen Sie auch
NEOVACS - Corporate Communication & Investor Relations
Charlène Masson
+33 1 53 10 93 00
cmasson@neovacs.com
[1] Cf. Press Release published February 21, 2017- https://bit.ly/2LDSG98
[2] Cf. Press Release published July 3 , 2018 - https://bit.ly/2MLYa2D
[3] https://www.ncbi.nlm.nih.gov/pubmed/21148605
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: NEOVACS via Globenewswire